⌕
Enliven Therapeutics · ELVN · Nasdaq
Tenet 59 · Mixed
Compare
$47.62−2.42%At closeTenet 59 · Mixed
$47.62−1.18 (−2.42%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Enliven Therapeutics (ELVN) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● PRNewsWireNov 5, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update

Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial  On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash equivalents and marketable…

● PRNewsWireOct 14, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year

Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness Enliven continues preparation for late-stage development and commercialization, as it plans to in…

● PRNewsWireOct 6, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia

Enliven remains on track to initiate ENABLE-2 before year-end 2026 BURLINGAME, Calif., Oct. 6, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical c…

● Defense WorldOct 6, 2026 · 10:20 ET
Enliven Therapeutics (NASDAQ:ELVN) Stock Falls 4.5% Following Insider Selling

Enliven Therapeutics, Inc. (NASDAQ: ELVN - Get Free Report) shares fell 4.5% during mid-day trading on Tuesday following insider selling activity. The company traded as low as $43.20 and last traded at $43.4350. 62,397 s…

● BenzingaOct 2, 2026 · 08:24 ET
This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.…

● Seeking AlphaSep 16, 2026 · 18:31 ET
Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

● PRNewsWireSep 3, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Enliven Therapeutics to Present at Upcoming Investor Conferences

BURLINGAME, Calif., Sept. 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule …

● Seeking AlphaSep 3, 2026 · 09:48 ET
Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing

Enliven Therapeutics is positioned as a late-stage, well-capitalized biotech with $895M cash, funding operations into 2030 and the pivotal ENABLE-2 trial. ELVN-001 targets chronic myeloid leukemia as a selective ATP-comp…

● PRNewsWireAug 31, 2026 · 18:05 ETCOMPANY'S OWN WORDS
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

BURLINGAME, Calif., Aug. 31, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule …

● Defense WorldAug 28, 2026 · 04:12 ET
BlackRock Inc. Invests $221.25 Million in Enliven Therapeutics, Inc. $ELVN

BlackRock Inc. acquired a new stake in shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 4,359,704 shar…

● BenzingaAug 18, 2026 · 13:58 ET
Enliven's Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says

Enliven Therapeutics Inc. (NASDAQ:ELVN) drew an Outperform rating from William Blair on Tuesday as the firm initiated coverage, citing the potential for lead drug candidate ELVN-001 to reshape treatment of chronic myeloi…

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just ELVN · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.